Fortress Biotech, Inc. FBIO revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Fortress Biotech, Inc. reported revenue across 2 business segments; the largest, Journey, was $61.9M (+10.2% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Journey$61.9Mshare n/a+10.2% yoy
- Avenue Therapeutics Inc$1.4Mshare n/ano prior
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Checkpoint-$38M54.2%-32.3% yoy
- Fortress Biotech Inc-$18.5M26.3%+42.3% yoy
- Journey-$8.17M11.6%-40.3% yoy
- Avenue Therapeutics Inc-$3.08M4.4%-72.7% yoy
- Mustang Therapeutics Inc-$2.43M3.5%-85.0% yoy
Members sum to the consolidated -$70.2M for this period.
- Qbrexza$25M40.8%-0.4% yoy
- Emrosi$14.7M24.1%no prior
- Accutane$12.9M21.0%-33.6% yoy
- Foam Franchise Products$5.86M9.6%-11.9% yoy
- Other Legacy Product Revenue$2.74M4.5%-30.9% yoy
- Royalty$00.0%no prior
Members sum to the consolidated $61.2M for this period.
- Journey$16M99.5%no prior
- Fortress Biotech Inc$77K0.5%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.